Intestinal mucositis is a common side effect of anticancer regimens that exerts a negative impact on chemotherapy. Superoxide dismutase (SOD) is a potential therapy for mucositis but efficient product is not available because the enzyme is degraded following oral administration or induces an immune reaction after intravascular infusion. Multi-modified Stable Anti-Oxidant Enzymes® (MS-AOE®) is a new recombinant SOD with better resistance to pepsin and trypsin. We referred it as MS-SOD to distinguish from other SODs. In this study we investigated its potential to alleviate 5-FU-induced intestinal injury and the mechanisms. An intestinal mucositis model was established in C57/BL6 mice by 5-day administration of 5-FU (50 mg/kg every day, ip). MS-SOD (800 IU/10 g, 1g) was given once daily for 9 days. 5-FU caused severe mucositis with intestinal morphological damage, bodyweight loss and diarrhea; MS-SOD significantly decreased the severity. 5-FU markedly increased reactive oxygen species (ROS) and inflammatory cytokines in the intestine which were ameliorated by MS-SOD. Furthermore, MS-SOD modified intestinal microbes, particularly reduced Verrucomicrobia, compared with the 5-FU group. In Caco-2 cells, MS-SOD (250–1000 U/mL) dose-dependently decreased tBHP-induced ROS generation. In RAW264.7 cells, MS-SOD (500 U/mL) had no effect on LPS-induced inflammatory cytokines, but inhibited iNOS expression. These results demonstrate that MS-SOD can scavenge ROS at the initial stage of injury, thus play an indirect role in anti-inflammatory and barrier protein protection. In conclusion, MS-SOD attenuates 5-FU-induced intestinal mucositis by suppressing oxidative stress and inflammation, and influencing microbes. MS-SOD may exert beneficial effect in prevention of intestinal mucositis during chemotherapy in clinic.

Keywords: manganese superoxide dismutase; 5-fluorouracil; chemotherapy; intestinal mucositis; diarrhea; oxidative stress; cytokines; intestinal microbes

Acta Pharmacologica Sinica (2020) 41:348–357; https://doi.org/10.1038/s41401-019-0295-8
poor resistance to high temperature or long-term storage in the drug preparation process. Even worse, because SOD is a macromolecule, transdermal absorption is limited, and SOD is easily digested and degraded by proteases in the gastrointestinal tract when orally administered.

MS-Superoxide Dismutase (MS-SOD) [15] is a new and highly stable manganese SOD obtained from a mutant high-temperature-resistant SOD strain. Compared with wild-type SOD and ordinary heat-resistant SODs, MS-SOD is more stable and shows better resistance to pepsin and trypsin, making MS-SOD a potential candidate for clinical development. MS-SOD is thus expected to be a new treatment for intestinal mucositis.

In addition, MS-SOD has been prescribed to treat gastrointestinal disorders and shown promise in alleviating the symptoms of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in zebrafish by markedly modulating inflammation and ulceration [15]. However, no further research on MS-SOD has been conducted in rodents, and whether MS-SOD is effective against chemotherapy-induced intestinal mucositis remains unknown. Therefore, in the current study, the effect of MS-SOD on 5-FU-induced intestinal mucositis was investigated in mice. MS-SOD treatment was found to reduce intestinal injury by attenuating morphological damage, bodyweight loss, and diarrhea. The influence of MS-SOD on oxidative stress, inflammation and intestinal microbes was further explored.

MATERIALS AND METHODS

Animals and experimental design

This study was conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals by the National Institutes of Health. The protocols were approved by the Committee on Ethics of Shanghai Institute of Materia Medica. Briefly, 6- to 8-week-old male specific pathogen-free C57/BL6 mice weighing 20–24 g were obtained from Shanghai Laboratory Animal Co. (Shanghai, China). All mice were maintained in plastic cages with free access to food and water and housed at 20–25 °C with a 12 h light/dark cycle. The mice were fed for one week to acclimate them to the environment before the experiment. The animals were distributed as follows: Group I—Control (untreated), Group II—5-FU (vehicle alone), and Group III—5-FU + MS-SOD. Intestinal mucositis was induced in Groups II and III via the intraperitoneal administration of 50 mg/kg 5-FU (Sigma-Aldrich, St Louis, MO, USA) for 5 days [16]. Mice in Groups II and III were also treated orally (by gavage) with water or MS-SOD, respectively, for 9 days, while vehicle was administered to the mice in Group I. On the 4th, 6th, 8th and 10th days, the animals were sacrificed (n = 6/group). Body weights, intestine lengths, and the results of diarrhea assessment and histopathological analysis were recorded for all animals. In the other assays, the animals were sacrificed on day 6.

Chemicals

5-FU was dissolved in a 5% glucose solution at a concentration of 5 mg/mL. MS-SOD (Redox, Suzhou, China, 4200 U/mg) was dissolved in water at a concentration of 1.9 mg/mL. All drugs were prepared immediately before use and administered via intraperitoneal (i.p.) injection or intragastrically (i.g.) at a volume of 0.1 mL/10 g of body weight.

Assessment of body weight and diarrhea

The animals were weighed daily during the induction process, and the results are expressed as variation in body weight (%) relative to the initial weight at the beginning of the experiment. Diarrhea severity was scored using the following scale: 0, normal (normal stool); 1, minimal (soft stool); 2, slight (slightly wet and soft stool); 3, moderate (wet and unformed stool with moderate perianal staining of the coat); or 4, severe (watery stool with severe perianal staining of the coat). The number of diarrhea scores of 0 to 4 and the average diarrhea score were used to evaluate the severity of diarrhea [17]. The first day on which the severity of diarrhea was observed was treated as the “onset of diarrhea.” The bleeding score was detected using fecal occult blood (OB) test paper (BASO Diagnostics Inc., Zhuhai, China) [18].

Intestinal length measurement and histopathological analysis

The intestine of each animal was dissected, and its length was measured. Then, the small intestine and large intestine were washed with phosphate-buffered saline (PBS) and fixed in 10% phosphate-buffered formalin (pH 7.4) for histopathological evaluation. Tissue samples were then dehydrated and embedded in paraffin, sectioned (4 μm thickness), and stained with hematoxylin and eosin (H&E). Histological lesions were scored by a pathologist at the Center for Drug Safety Evaluation and Research at the Shanghai Institute of Materia Medica. Each slide was subsequently photographed using a light microscope (Axio Scope A1, Carl Zeiss, Jena, TH, Germany) with a ×20 objective lens.

Determination of mRNA expression via quantitative PCR

The small intestine tissue was washed with PBS, and total RNA was extracted from 20-mg samples using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. A PrimeScript RT kit (TaKaRa, Osaka, Japan) was used for cDNA synthesis using quantitative real-time polymerase chain reaction (qPCR) with a Rotor-Gene Qplex HRM system (Qiagen, Redwood City, CA, USA) using SYBR® Premix Ex Taq™ II (TaKaRa). The specific primer sequences used to amplify GAPDH, IL-6, IL-17a, CXCL1, CXCL2, Claudin-2 and Occludin are listed in Table 1. All mRNA expression levels were calculated using the comparative CT (ΔΔCT) method (normalized to the mean value of the control group).

Preparation of intestinal tissue homogenates

A small intestinal segment was removed from each animal and stored at −20 °C for subsequent analysis. After thawing, 100 mg of each intestinal sample was washed in PBS (pH 6.0) and transferred to a tube, and 1 mL of PBS was added to each tube. The tissues were then homogenized using a Scientz-48 tissue grinder (Ningbo Scientz Biotechnology Co., Ningbo, China) and then centrifuged at 400 × g for 10 min at 4 °C. The supernatant was collected and the protein concentration was determined using the Bicinchoninic Acid (BCA) protein assay kit (Beyotime, Shanghai, China). A 20-μL supernatant was diluted to 50 μL with PBS and added to each well of a 96-well plate. A specific protein assay kit (Multiskan, ThermoFisher Scientific, Waltham, MA, USA) was used for subsequent analysis.

Table 1. Primer sequences for quantitative real-time PCR analysis

| Gene   | Forward primer sequences | Reverse primer sequences |
|--------|--------------------------|--------------------------|
| GAPDH  | Forward (5′−3′)          | Reverse (3′−5′)          |
|        | AACCTTTGCGATTGTGGAAGG    | ACACATGGGGGTAGAACA       |
| Nrf2   | Forward (5′−3′)          | Reverse (3′−5′)          |
|        | CTTTGATCCAGCAAGGAAGC     | AGGCACTGTGGTGGAAGTGG     |
| Occludin| Forward (5′−3′)         | Reverse (3′−5′)          |
|        | ATGGAAGGCGATACATCC       | TTCTGTCTTCCCTCTCCG       |
| IL-6   | Forward (5′−3′)          | Reverse (3′−5′)          |
|        | GATCCTTCATCCAGGTCCTTC   | AGACAGGCTGTGGAAGTGGTA    |
| IL-17α | Forward (5′−3′)          | Reverse (3′−5′)          |
|        | GTGAAAGGGACAGGATCAT      | GCGCAAGGGAGTAAGAAGCT     |
| IL-22  | Forward (5′−3′)          | Reverse (3′−5′)          |
|        | AGCTGCTGTCTCTCATTGC     | GACGATGTTAGGCTGCCGAA     |
| IL-1β  | Forward (3′−5′)          | Reverse (3′−5′)          |
|        | GAAATGGCACCATTGTTGAGG    | TGGATGCTCCTCATTGACAG    |
| CXCL1  | Forward (5′−3′)          | Reverse (3′−5′)          |
|        | GCTCCCTTTGGTCAAGAAATTT  | TCACAGACAGGCTGCACCA     |
| CXCL2  | Forward (5′−3′)          | Reverse (3′−5′)          |
|        | CCTGGCAAAGGTGAGCTTC     | TTTTACCGCCACCATTGAGG    |

Acta Pharmacologica Sinica (2020) 41:348 – 357
4 °C for 15 min. The obtained supernatants were used in assays. The experiments were carried out in triplicate.

ROS and detection of total antioxidant capacity
Intestinal tissue homogenates were centrifuged, washed in PBS and loaded with 50 μM 2',7'-dichlorofluorescein-diacetate (DCFDA) for 10 min at 37 °C to determine the ROS content. Fluorescence was detected with a BIOTEK 54 ML FPTAD instrument (BioTek, Milton, VT, USA). The total antioxidant capacity was detected using a T-AOC assay kit (Beyotime, Nanjing, China). Moreover, a mouse myeloperoxidase (MPO) ELISA kit (Cusabio, Cambridge, MA, USA) was used to detect MPO content.

Western blotting
Mouse intestinal tissues (30 mg) were lysed with radioimmunoprecipitation assay buffer (Beyotime). Protein lysates were separated on 10% SDS-PAGE gels and electrophoretically transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk and incubated overnight at 4 °C with antibodies against occludin (Abcam, Cambridge, MA, USA), nuclear factor (erythroid-derived 2)-like 2 (Nrf-2; Enzo Life Sciences, Inc., Farmingdale, NJ, USA) and heme oxygenase 1 (HO-1; Enzo Life Sciences, Inc.). The membranes were then incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Protein band chemiluminescence was detected using an ECL Plus immunoblot detection system (Millipore) and analyzed by densitometry. The housekeeping gene was detected on the same membrane using a monoclonal rabbit anti-GAPDH antibody (1:5000 dilution; ab9485, Abcam) to confirm equivalent protein loading.

Bacterial DNA extraction/sequencing and analysis of bacterial 16S rDNA
Fecal samples were suspended in PBS and centrifuged at 14 000 x g, and the pellets were resuspended in 100 mM Tris-HCl (pH 9.0) containing 40 mM EDTA and 1% sodium dodecyl sulfate. The suspension was mixed with buffer-saturated phenol and 0.1-mm glass beads and shaken at 800 x g for 10 s. After centrifugation at 14 000 x g for 5 min, the supernatant was collected, extracted with phenol-chloroform and precipitated with isopropanol. The resulting DNA pellet was washed with 70% ethanol, dried and dissolved in 10 mM Tris-HCl (pH 8.0) with 1 mM EDTA. The composition of the intestinal microbial community was analyzed based on the V3-V4 region in 16S rRNA (Majorbio, Shanghai, China).

In vitro cell system tests
Human colorectal adenocarcinoma (Caco2) cells were treated with tert-butyl hydroperoxide (tBHP) to induce the generation of ROS. In brief, 31.25 μM tBHP was added to wells containing Caco2 cells for 1 h, and MS-SOD at the indicated concentrations was also added simultaneously (Supplementary Fig. S1). Cells were incubated for 30 min with 25 mM DCFH-DA, and the ROS content was then detected with the fluorescent method described above.

RAW264.7 cells were preincubated with 500 U/mL MS-SOD for 6 h and then stimulated with 10 μg/mL LPS to induce the generation of inflammatory cytokines. Samples were collected 6 h after LPS stimulation, and IL-1β, IL-6, TNF-α and inducible nitric oxide synthase (iNOS) mRNA expression levels were measured as described above.

Statistical analysis
Data were analyzed and graphed using GraphPad Prism software (version 5.03; GraphPad Software, Inc., La Jolla, CA, USA) and are expressed as the means ± SEM. Student’s t-tests were used to determine the significance of differences. A Wilcoxon rank-sum test was used to analyze data at the phylum level. P < 0.05 indicated statistical significance.

RESULTS
MS-SOD reduced body weight loss and diarrhea induced by 5-FU
Repeated 5-FU administration (50 mg/kg) for 5 days (days 1–5) decreased the body weights of the animals (Fig. 1a, b). Significant body weight loss was observed on day 3 and reached 16% reduction on day 5. The body weights gradually recovered after 5-FU withdrawal. Once-daily administration of MS-SOD (800 IU/10 g) until day 9 reduced body weight loss during or after 5-FU treatment, and this effect was significant on days 5, 8 and 9. Diarrhea and fecal blood are common gastrointestinal symptoms of mucositis following chemotherapy [19]. No abnormalities were observed in the control group. However, 5-FU treatment caused an elevation in the diarrhea score on day 4, and these symptoms persisted after 5-FU withdrawal. MS-SOD treatment had an antidiarreal effect (Fig. 1c). Consistent with 5-FU-induced diarrhea, fecal blood was also observed on day 4, and the fecal blood score was worsened daily until sacrifice. A reduction in the fecal blood score was also found in the MS-SOD treatment group (Fig. 1d).

MS-SOD attenuated intestinal injury
The intestinal damage induced by chemotherapy is partially manifested by a reduction in intestinal length [20]. In the current study, the lengths of both the small intestine and colon were reduced in 5-FU-treated animals, and a significant reduction in small intestine and colon length was observed on day 6. Treatment with MS-SOD prevented this decrease (Fig. 2b). Furthermore, to evaluate 5-FU-induced mucosal damage at the microscopic level, H&E-stained sections of the small intestine and colon were examined. Villus height and crypt depth were reduced throughout the small intestine in all 5-FU-treated groups compared with those in the control group. Mucosal erosion and subacute inflammation occurred in the colons of mice in the 5-FU-treated groups. However, in the MS-SOD-treated mice, the villus height, crypt depth, mucosal erosion and subacute inflammation in the intestine were improved compared with those in mice in the 5-FU group, and this difference was significant on day 6. Furthermore, the mucosa was thicker following MS-SOD treatment compared with that in the 5-FU group (Fig. 2a). The reduction in intestine length observed with 5-FU treatment was gradually reversed in the mice after 5-FU withdrawal.

MS-SOD increased occludin expression
Occludin is an important protein for tight junction stability and barrier function [21]. Previous studies have indicated that mice that do not express occludin show morphological instability in several epithelial tissues and chronic inflammation [21]. The occludin mRNA (Table 1) and protein levels in the small intestine were decreased in mice after 5 days of treatment with 5-FU, which was in accordance with the observed microscopic damage. However, the occludin mRNA and protein expression levels in MS-SOD-treated mice were increased compared with those in the 5-FU group (Fig. 3a).

MS-SOD decreased cytokine expression
After treatment with 5-FU, the expression of IL-6, IL-17a, IL-22, CXCL1 and CXCL2 mRNA in the small intestine was upregulated [22, 23]. The concentration of IL-6 in the serum was also found to be increased. IL-6 is one of the main proinflammatory cytokines. IL-17a and IL-22, which are signature cytokines of T helper cell 17, might initiate and amplify multiple proinflammatory pathways and have also been reported to be related to Crohn’s disease and ulcerative colitis. It has been reported that 5-FU could increase CXCL1 and CXCL2 expression in the intestinal tracts of mice, which may be related to the degree of inflammation and diarrhea [24]. These cytokines were downregulated in MS-SOD-treated mice (Fig. 3c, d). Moreover, a significant increase in MPO content was found in the 5-FU group (P < 0.05, Fig. 3b), but MS-SOD did not significantly decrease the MPO level after intervention.
Fig. 1 Schedule for the administration and effects of MS-SOD on 5-FU-induced changes in body weight, diarrhea and fecal blood score in mice. MS-SOD (800 IU/10 g, i.g.) or vehicle (diluted water, i.g.) was administered from day 1 to day 9, and 5-FU (50 mg/kg, i.p.) or vehicle (saline, i.p.) was administered from day 1 to day 5. Animals were sacrificed on days 4, 6, 8 and 10 (n = 6/group) (a). Overview of the study setup. The body weight of mice treated with vehicle or MS-SOD was recorded daily (b), and diarrhea and fecal blood scores (c, d) were recorded from day 4. Significant body weight loss induced by 5-FU was observed on day 3, and MS-SOD significantly reduced this loss on days 5, 8 and 9. Diarrhea and the fecal blood score were worsened daily in the vehicle group, but MS-SOD treatment reduced the score each day. The data are presented as the means ± SEM (n = 6); *P < 0.05, **P < 0.01, and ***P < 0.001 according to unpaired t-tests.

Fig. 2 Histological changes and shortening of the small intestine and colon after 5-FU administration and MS-SOD treatment. Five days after 5-FU challenge, the small intestine (a) and colon (b) from control, 5-FU, and 5-FU + MS-SOD mice were sectioned and prepared for H&E staining (×200), and shortening of the small intestine (c) and colon (d) was assessed to evaluate the severity of mucositis. Villus height and crypt depth reduction in the small intestine occurred in the 5-FU group, accompanied by mucosal erosion and subacute inflammation in the colon. Additionally, the intestinal length was decreased due to atrophy induced by 5-FU, but MS-SOD treatment improved the symptoms. The data are presented as the means ± SEM (n = 6); *P < 0.05 according to unpaired t-tests.
MS-SOD reduced ROS content and elevated antioxidant capacity
Following 5-FU injection, ROS were released in the small intestine, and their levels were significantly increased in the 5-FU group compared with those in the control [11]. However, a reduction in ROS was observed in MS-SOD-treated mice (Fig. 4a). The total antioxidant capacity in the small intestine were decreased in mice after 5 days of 5-FU injection but were increased in the MS-SOD group. The mRNA expression levels of the main pro-inflammatory cytokines, IL-6, IL-17α and IL-22 as well as the chemokines CXCL1 and CXCL2, were upregulated in the 5-FU group, but these cytokines were downregulated in MS-SOD-treated mice. The serum IL-6 concentration was in accordance with the mRNA level. ELISA method was used for MPO content measure. MPO content in intestinal tissue homogenates was significantly increased in the 5-FU group, but did not decrease in MS-SOD group (b). The data are shown as the means ± SEM (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001. In a, the repeated blots in each group indicate three individuals.

MS-SOD had an effect on intestinal microbes
The gastrointestinal tract harbors a wide variety of microorganisms known as intestinal microbes. Studies have found that 5-FU administration changes the intestinal microbes in mice and that these changes are one of the factors associated with intestinal mucosal injury [26]. In this study, second-generation sequencing was used to determine and quantify the intestinal flora in mice. At the phylum level, the abundance of Bacteroides decreased, but the abundance of Lachnospiraceae and Verrucomicrobia increased in the 5-FU group compared with that in the control group. MS-SOD reversed these effects (Fig. 5a). The specific data are shown in Table 2. We also performed the analysis at the genus level among the three groups (Fig. 5b).

MS-SOD inhibited tBHP-induced ROS generation in Caco-2 cells
As shown by the results in Fig. 6, MS-SOD decreased ROS generation in Caco-2 cells in a dose-dependent manner, which indicated that MS-SOD can dose-dependently inhibit tBHP-induced ROS generation.

MS-SOD inhibited LPS-induced ROS generation in RAW264.7 cells
MS-SOD (500 U/mL) had no significant effect on inflammatory cytokines but inhibited the expression of iNOS mRNA (Fig. 7). iNOS...
is mainly produced in pathological conditions, which further damages cells [27]. Therefore, inhibiting iNOS expression may also be a target for the treatment of inflammation [27, 28].

**DISCUSSION**

5-FU is one of the most common chemotherapeutic agents used for the treatment of malignant tumors [29]. However, 5-FU frequently causes intestinal mucositis, which is accompanied by severe diarrhea [2]. The serious side effects of 5-FU impair patient quality of life and might lead to the discontinuation of cancer chemotherapy. Therefore, effective countermeasures against 5-FU-induced intestinal mucositis are necessary.

In the current study, we found that the novel SOD product MS-SOD contributes to a reduction in 5-FU-induced intestinal mucositis. MS-SOD was constructed through genetic modification of the thermophilic HB27-encoded SOD gene and expressed in competent *E. coli* BL21 for batch production [15]. Compared with the reported products of thermophilic bacteria extraction, MS-SOD has a comprehensive advantage in its resistance to high temperature and pepsin and trypsin treatment, which precludes the generation of oral degradation fragments and maintains MS-SOD activity after its oral administration [15]. Therefore, MS-SOD has been proposed as a therapeutic agent targeted to the intestine with demonstrated efficacy in the treatment of 5-FU-induced mucositis.

Several studies have demonstrated that the administration of 5-FU to experimental animals produces diarrhea and decreases body weight, accompanied by morphological damage to the intestine [16]. Our study indicated that the repeated administration of 5-FU (50 mg/kg) to mice causes severe intestinal mucositis. This mucositis is morphologically characterized by shortening of the villus height and the destruction of crypts in the small intestine. Once-daily administration of MS-SOD reduced the severity of 5-FU-induced morphological intestinal damage and clinical symptoms, including diarrhea and body weight loss.

---

Fig. 4 Effects of MS-SOD on ROS levels and antioxidant capacity in the small intestine during 5-FU treatment. The ROS content and total antioxidant capacity of the small intestine at different times were detected using commercial kits (a, b). qPCR analysis was performed to measure the transcription level of Nrf2. Western blotting was performed to measure the level of HO-1 and Nrf2 translation (c). Activity of SOD and the content of superoxide were detected via kits (d). MS-SOD reduced the ROS content and increased the total antioxidant capacity in the small intestine during 5-FU injection. MS-SOD increased both Nrf2 and HO-1 expression in the small intestine after 5 days of 5-FU treatment. MS-SOD also increased the activity of SOD and decreased the superoxide content. The data are shown as the means ± SEM (*n* = 6). *P* < 0.05, **P** < 0.01, ***P** < 0.001. In (c), the repeated blots in each group indicate three individuals.
Fig. 5  Effects of MS-SOD on gut microbes after 5-FU treatment. Cecum feces were collected on day 6, and the relative abundance of microbes was analyzed via next-generation sequencing of bacterial 16S DNA. At the phylum level, 5-FU treatment decreased the abundance of Bacteroides but increased the abundance of Lachnospiraceae and Verrucomicrobia compared with the control mice. MS-SOD reversed this situation (a). At the genus level, more detailed changes were observed (b).
SOD alleviated the mucositis caused by 5-FU primarily in the renewal after the withdrawal of 5-FU. The administration of MS-SOD during the initial stage of the experiment but exhibited self-withdrawal of 5-FU once daily for 5 days showed severe mucositis gradually [11]. ROS induction in particular is the initial event in intestinal cascade of injury. We did not emphasize the recovery stage in the mice because of the ability of the intestinal epithelium to renew. The mice appeared to experience faster recovery after the withdrawal of 5-FU due to the effects of MS-SOD.

Although the pathogenesis of 5-FU-induced intestinal mucositis is not fully understood, several pathogenic elements in addition to its direct cytotoxicity are thought to be involved; these elements include ROS, abnormal inflammation and intestinal flora disorder [11]. ROS induction in particular is the initial event in intestinal mucositis induced by 5-FU [11]. Then, excess ROS levels activate a cascade of inflammatory pathways. ROS overproduction and inflammation destroy the antioxidant system, and ROS cannot be scavenged in time, which causes oxidative stress and cell damage.

Table 2. Effect of MS-SOD on 5-FU-induced changes in mouse bacterial flora

| Condition          | Bacteroidetes | Firmicutes | Proteobacteria | Actinobacteria | Tenericutes | Verrucomicrobia |
|--------------------|---------------|------------|----------------|----------------|-------------|----------------|
| Control            | 57 ± 9.42     | 42.39 ± 9.51 | 0.22 ± 0.13    | 0.35 ± 0.21    | 0.02 ± 0.02 | 0 ± 0          |
| 5-FU               | 50.76 ± 10.24 | 47.93 ± 10.64 | 0.86 ± 0.75    | 0.16 ± 0.11    | 0.16 ± 0.067 | 0.12 ± 0.17    |
| 5-FU + MS-SOD      | 69.21 ± 6.50  | 27.95 ± 5.76  | 2.48 ± 4.77    | 0.18 ± 0.11    | 0.17 ± 0.15  | 0 ± 0          |

Animals were administered 50 mg/kg 5-FU via intraperitoneal injection once daily for 5 days (days 1 to 5), with or without 800 U/10 g MS-SOD coadministered daily. Feces were collected on day 6, and bacterial 16S rDNA was quantified via PCR. The data are shown as the mean (% ± SD) (%) values from 6 animals per group. *P < 0.05, **P < 0.01 vs. control; †P < 0.05, ††P < 0.01 vs. animals treated with 5-FU only.

The loss of mucosal integrity results in notably painful lesions that are prone to superficial bacterial colonization. These breaks in the mucosa serve as portals of entry for numerous microorganisms.

Our study determined the overproduction of ROS after the administration of 5-FU. These findings suggest that ROS are important in the initiation of 5-FU-induced intestinal mucositis. ROS levels were significantly lower after the administration of MS-SOD. MS-SOD attenuated oxidative stress in response to 5-FU and induced the antioxidant HO-1-Nrf2 pathway. Therefore, MS-SOD significantly reduces 5-FU-induced intestinal mucositis via inhibiting oxidative stress in intestinal crypts (Fig. 8).

Indeed, several studies have demonstrated that 5-FU-induced apoptosis can be potentially prevented by inhibiting cytokine expression. In the current study, 5-FU administration caused the upregulation of cytokines related to inflammation and diarrhea, IL-6, IL-17α, IL-22, CXCL1 and CXCL2, in the small intestine. Interestingly, MS-SOD significantly attenuated the regulation of these cytokines. We also detected the concentration of cytokines in both the serum and intestine, but most of these factors were difficult to detect in the intestine. Therefore, we chose to detect mRNA expression, and most of the cytokines in the intestine did not exhibit differences in expression between the 5-FU-treated mice and MS-SOD-treated mice. Indeed, orally administered MS-SOD did not circulate in the blood and thus might have no effect on hematologic indexes (Supplementary Fig. S2).

Basic and clinical studies have demonstrated that cancer chemotherapy induces dysbiosis [18]. We also examined the influence of 5-FU and MS-SOD on the intestinal flora in mice. 5-FU decreased the relative abundance of Bacteroides and increased the relative abundance of Lachnospiraceae compared with their abundance in the control group. 5-FU treatment also increased the abundance of Verrucomicrobia. Akkermansia muciniphila, which belongs to the phylum Verrucomicrobia, is well known to degrade mucin [31] and promote intestinal inflammation. Interestingly, MS-SOD treatment reversed the changes in the 5-FU-treated mice reported above. Therefore, MS-SOD likely reduces 5-FU-induced mucositis by influencing the intestinal flora.

Furthermore, in vitro studies indicated that MS-SOD inhibited iNOS generation induced by LPS in a macrophage cell line and t-BHP in Caco2 cells. iNOS is mainly produced during pathological states and may be induced by inflammatory substances, thus leading to a high level of NO production, further damaging cells and worsening inflammation. Therefore, NOS, the target of MS-SOD, is inhibited by MS-SOD to treat inflammatory reactions. Mucosal damage is accompanied by barrier damage, including mechanical barrier, chemical barrier, biological barriers and immune barrier damage, among which mechanical barrier damage is the most important. The intestinal barrier structure depends on tight junctions (TJs) and adhesion proteins [32]. TJs are closely related to the development of intestinal diseases [32], and surface bacteria colonization is facile when there are cracks in
the mucosa. The connected structural proteins include transmembrane proteins, cytoplasmic proteins and cytoskeletal proteins. These transmembrane proteins primarily include occludin [33, 34], claudins, and junction adhesion molecule (JAM). Claudin-2 is unregulated in the small and large intestine, where it contributes to diarrhea via a leak flux mechanism [34]. The expression of most TJ proteins was low after 5-FU administration. However, MS-SOD did not obviously protect these proteins. Therefore, we hypothesized that 5-FU destroyed the composition of these proteins through damage to the intestinal mucosa epithelium, while MS-SOD failed to protect these proteins.

A model proposed by Sonis has been widely cited to explain the basic pathophysiology of mucosal injury [10]. When inflammation occurs, the antioxidant system is destroyed, and ROS cannot be cleared in time, leading to oxidative stress and damage to intracellular targets. Proinflammatory cytokines are released after their activation by chemotherapy and ROS, leading to tissue damage and apoptosis. The release of a large number of proinflammatory cytokines enhances the entire inflammatory process and prolongs tissue damage. These effects primarily occur in the submucosa and basal epithelium. At this stage, although the tissue biology has changed, no obvious mucosal injury is observed clinically. Intestinal mucosal ulcers and atrophic changes are the apex events in tissue damage along with stem cell death. The integrity of the intestinal epithelium is destroyed,
and its function is impaired. Patients usually have diarrhea at this stage. In the present study, we propose that the main protective effect of MS-SOD against intestinal mucosal injury is its effective scavenging of ROS at the initial stage of mucosal injury and that MS-SOD thus plays an indirect role in inflammation and barrier protein protection, thereby reducing the degree of intestinal mucosal injury.

In conclusion, we found that MS-SOD reduced 5-FU-induced mucositis in mice by improving oxidative stress, inflammation and dysbiosis. Therefore, MS-SOD might have clinical benefits for the prevention of intestinal mucositis during cancer chemotherapy. However, it is important to investigate the effects of MS-SOD on mucositis induced by other chemotherapy drugs to reach a more convincing conclusion that MS-SOD is an effective treatment for intestinal mucositis in chemotherapy.

ACKNOWLEDGEMENTS

This study was supported by the National New Drug Creation Program of China (2015ZX09501007-001 to Jian-hua Sun and 2018ZX09201017-004 to Li-kun Gong) and the “Strategic Priority Research Program” of the Chinese Academy of Sciences (XDA12050305 to Li-kun Gong).

AUTHOR CONTRIBUTIONS

XXY, YTZ, FGM and LKG designed the research and wrote the manuscript. XXY, HLL, SYW, XLY, and JHS conducted the experiments. HLL contributed to the pathological analysis, and YTZ performed data analysis.

ADDITIONAL INFORMATION

The online version of this article (https://doi.org/10.1038/s41401-019-0295-8) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

REFERENCES

1. Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, et al. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the university of Texas MD Anderson cancer center symptom inventory-head and neck module. Cancer. 2014;120:1975–84.
2. Harris DJ. Cancer treatment-induced mucositis pain: strategies for assessment and management. Ther Clin Risk Manag. 2006;2:251–8.
3. Swami U, Goel S, Mani S. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr Drug Targets. 2013;14:777–97.
4. Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, de Braud F, et al. Incidence and relative risk of grade 3 and 4 diarrhea in patients treated with capetcitabine or 5-fluorouracil: a meta-analysis of published trials. Br J Clin Pharmacol. 2014;78:1228–37.
5. Simone NL, Menard C, Soule BP, Albert PS, Guion P, Smith S, et al. Intraepithelial amnionitis during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by epic score. Int J Radiat Oncol Biol Phys. 2008;70:90–5.
6. Zhou YF, Sridhar R, Shan L, Sha W, Gu BX, Sukumar S, Lopereamid, an FDA-approved antidiarheal drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. Cancer Invest. 2012;30:119–25.
7. Deng C, Deng B, Jia LQ, Tan HY. Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhea: protocol for a systematic review. BMJ Open. 2017;7:e014916.
8. Huang JH, Cao YF, Luo C, Wu LC, Gao F. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Crit Care. 2010;14:R194.
9. Aggarwal BB, Piasad S, Reuter S, Kannappan R, Yadav VR, Park B, et al. Identification of novel anti-inflammatory agents from ayurvedic medicine for prevention of chronic diseases: “Reverse Pharmacology” and “Bedside to Bench” approach. Curr Drug Targets. 2011;12:1595–63.
10. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–84.

11. Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev. 2014;94:329–54.
12. Zhang XC, Epperly MW, Kay MA, Chen ZY, Dixon T, Franchi D, et al. Radioprotection in vitro and in vivo by minicircle plasmid carrying the human manganese superoxide dismutase transgene. Hum Gene Ther. 2008;19:820–6.
13. Ahlengard S, Tufessson G, Pettersson H, Andersson T. Treatment of traumatic arthritis in the horse with Intra-Articular Orgeotin (Palosein”). Equine Vet J. 1978;10:122–4.
14. Goldberg LD, Crysler C. A single center, pilot, double-blinded, randomized, comparative, prospective clinical study to evaluate improvements in the structure and function of facial skin with tazarotene 0.1% cream alone and in combination with GliSODin® skin nutrients advanced anti-aging formula. Clin Cosmet Invest Dermatol. 2014;7:139–44.
15. Meng FG, inventors. Novel recombinant high-stability superoxide dismutase and application thereof. China patent. 2016,ZL201610099824.
16. Hamouda N, Sano T, Oikawa Y, Ozaki T, Shimakawa M, Matsumoto K, et al. Apoptosis, dysbiosis and expression of inflammatory cytokines are sequential events in the development of 5-fluorouracil-induced intestinal mucositis in mice. Basic Clin Pharmacol Toxicol. 2017;121:159–68.
17. Yasuda M, Kato S, Yamanaka N, Iimori M, Matsumoto K, Utsumi D, et al. S-HT3 receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. Br J Pharmacol. 2013;168:1388–400.
18. Li HL, Lu L, Wang XS, Qin LY, Wang P, Qiu SP, et al. Alteration of gut microbiota and inflammatory cytokine/chemokine profiles in 5-fluorouracil induced intestinal mucositis. Front Cell Infect Microbiol. 2017;7:455.
19. Liu ZZ, Xi J, Schroder S, Wang WG, Xie TP, Wang ZQ, et al. Chimonanthus nitens var. salicifolius aqueous extract protects against 5-fluorouracil induced gastrointestinal mucositis in a mouse model. Evid Based Complement Alternat Med. 2013;2013:789263.
20. Wright TH, Yazbeck R, Lynn KA, Whitford EJ, Cheah KY, Butler RN, et al. The herbal extract, Iberogast (R), improves jejunal integrity in rats with 5-fluorouracil (5-FU)-induced mucositis. Cancer Biol Ther. 2009;8:923–9.
21. Al-Sadi R, Khatib K, Guo SH, Ye DM, Youssif M, Ma T. Ocludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2011;300:G1054–64.
22. Lin Y, Lin Y, Lin L, Zheng CQ, IL-17/FN-gamma interactions regulate intestinal inflammation in TNBS-induced acute colitis. J Interferon Cytokine Res. 2012;32:548–56.
23. Hosseini MS, Mansourabadi AH, Shams A, Hassanzadeh M. The role of interleukin (IL-22) in immune response to human diseases. Int J Epidemiol. 2015;2:152–61.
24. Sakai H, Kai Y, Oguchi A, Kimura M, Tabata S, Yaegashi M, et al. Curcumin inhibits 5-fluorouracil-induced up-regulation of CXCL1 and CXCL2 of the colon associated with attenuation of diarrhea development. Basic Clin Pharmacol Toxicol. 2016;119:540–7.
25. Xu L, He SS, Yin P, Li DY, Mei C, Yu XH, et al. Punicalinagen induces Nrf2 translocation and HO-1 expression via PI3K/Akt, protecting rat intestinal epithelial cells from oxidative stress. Int J Hypertherm. 2016;32:2465–73.
26. Asakura H, Suzuki K, Kitahora T, Morizane T. Is there a link between food and intestinal microbes and the occurrence of Crohn’s disease and ulcerative colitis? J Gastroenterol Hepatol. 2008;23:1794–801.
27. Forstermann U, Seisa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829–37.
28. Hernandez-Savedra D, Zhou HF, McCord JM. Anti-inflammatory properties of a chimeric recombinant superoxide dismutase: SOD2/3. Biomed Pharmacother. 2005;59:204–8.
29. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.
30. van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009;71:241–60.
31. Ganesh BP, Köpfleisch R, Loh G, Blaut M. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella typhimurium-infected gnotobiotic mice. PLoS One. 2013;8:e74963.
32. Hu CA, Hou Y, Di Q, Qiu Y, Wu G, Kong X, et al. Autophagy and tight junction proteins in the intestine and intestinal diseases. Anim Nutr. 2015;1:43–7.
33. Weber CR, Shen L, Wu LC, Wang YM, Turner JR. Ocludin is required for tumor necrosis factor (TNF)-mediated regulation of tight junction (TJ) barrier function. Gastroenterology. 2011;140:564.
34. Luettig J, Rosenthal R, Barmeyer C, Schulzke JD. Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation. Tissue Barriers. 2015;3:e977176.